Ben (L) and Roland Buelow
Hitching a quick ride on the M&A train, AstraZeneca wagers $100M cash on T cell engager
AstraZeneca has engineered a $1.27 billion deal to acquire a small biotech and its T cell engager — with an eye to shaking up the standards …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
